Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline
HQ: NL
Founded: 2019
Series B
Sector: Health Care
Investment Raised: EUR 54M €
Valuation Remains Undisclosed
Investors: Ackermans & van Haaren Droia Ventures EQT life science Eurazeo Kurma Partners Polaris Partners Pureos Bioventures